Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday
01:44pm, Thursday, 06'th Feb 2025
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so quickly.
Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript
01:41pm, Thursday, 06'th Feb 2025
Bristol-Myers Squibb Company (NYSE:BMY ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Boar
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
01:11pm, Thursday, 06'th Feb 2025
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook
12:08pm, Thursday, 06'th Feb 2025
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday.
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q4 Earnings
10:36am, Thursday, 06'th Feb 2025
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall
Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue Estimates
09:10am, Thursday, 06'th Feb 2025
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
09:08am, Thursday, 06'th Feb 2025
On Thursday, Bristol Myers Squibb & Co BMY posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 billion.
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
07:01am, Thursday, 06'th Feb 2025
Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term growth. The company also issued a full-year
Trade Tracker: Josh Brown buys Bristol-Myers
01:28pm, Tuesday, 04'th Feb 2025
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's buying Bristol-Myers at these levels.
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
02:36pm, Monday, 03'rd Feb 2025
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
12:20pm, Monday, 03'rd Feb 2025
Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
11:41am, Monday, 03'rd Feb 2025
BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock.
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings
10:21am, Monday, 03'rd Feb 2025
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during t
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
08:32am, Monday, 03'rd Feb 2025
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. Howe
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
03:31pm, Friday, 31'st Jan 2025
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
